360 related articles for article (PubMed ID: 32847479)
1. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
2. Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm.
Piccini M; Loscocco GG; Gianfaldoni G; Grieco P; Palmieri G; Pilerci S; Scappini B; Bosi A
Ann Hematol; 2020 Apr; 99(4):907-909. PubMed ID: 32030448
[No Abstract] [Full Text] [Related]
3. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Lee SS; McCue D; Pemmaraju N
Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
[TBL] [Abstract][Full Text] [Related]
4. Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.
Wang Q; Zhao Y; Zang X; Zhou G; Liu Y; Feng Q; Li X; Wang W; Dong X; Liu X; Peng J; Liu C
Ann Hematol; 2024 Mar; 103(3):999-1005. PubMed ID: 38285081
[TBL] [Abstract][Full Text] [Related]
5. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
Egger A; Coello D; Kirsner RS; Brehm JE
J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
[TBL] [Abstract][Full Text] [Related]
6. Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation.
Wang SY; Thomassen K; Kurch L; Opitz S; Franke GN; Bach E; Platzbecker U; Kayser S
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e579-e582. PubMed ID: 33795208
[No Abstract] [Full Text] [Related]
7. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
Economides MP; McCue D; Lane AA; Pemmaraju N
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247
[No Abstract] [Full Text] [Related]
8. Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Alfayez M; Konopleva M; Pemmaraju N
Expert Opin Biol Ther; 2020 Feb; 20(2):115-123. PubMed ID: 31801379
[No Abstract] [Full Text] [Related]
9. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
[TBL] [Abstract][Full Text] [Related]
10. Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Morin A; Kechedjian F; Walton P; Tavakoli A
Clin J Oncol Nurs; 2021 Apr; 25(2):E10-E16. PubMed ID: 33739343
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax to treat relapsed blastic plasmacytoid dendritic cell neoplasm: A case-report and review of literature.
Beziat G; Ysebaert L; Gaudin C; Steinmeyer Z; Balardy L
Leuk Res; 2019 Oct; 85():106199. PubMed ID: 31415942
[No Abstract] [Full Text] [Related]
12. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
Hu X; Ediriwickrema A; Saleem A; Tan B; Pemmaraju N; Mannis GN
Leuk Res; 2024 Apr; 139():107479. PubMed ID: 38492495
[No Abstract] [Full Text] [Related]
13. Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.
Montero J; Stephansky J; Cai T; Griffin GK; Cabal-Hierro L; Togami K; Hogdal LJ; Galinsky I; Morgan EA; Aster JC; Davids MS; LeBoeuf NR; Stone RM; Konopleva M; Pemmaraju N; Letai A; Lane AA
Cancer Discov; 2017 Feb; 7(2):156-164. PubMed ID: 27986708
[TBL] [Abstract][Full Text] [Related]
14. Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm.
Tandon A; Zhang Y; Sokol L
Drugs Today (Barc); 2019 Dec; 55(12):735-742. PubMed ID: 31942876
[TBL] [Abstract][Full Text] [Related]
15. Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Luskin MR; Lane AA
Haematologica; 2024 Jan; 109(1):44-52. PubMed ID: 36951152
[TBL] [Abstract][Full Text] [Related]
16. Tagraxofusp in myeloid malignancies.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
Hematol Oncol; 2024 Jan; 42(1):e3234. PubMed ID: 37846131
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
Pemmaraju N; Madanat YF; Rizzieri D; Fazal S; Rampal R; Mannis G; Wang ES; Foran J; Lane AA
Leuk Lymphoma; 2024 May; 65(5):548-559. PubMed ID: 38391126
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective.
Mirgh S; Sharma A; Folbs B; Khushoo V; Kapoor J; Tejwani N; Ahmed R; Agrawal N; Choudhary PS; Mehta P; Bhurani D
Leuk Lymphoma; 2021 Dec; 62(12):3039-3042. PubMed ID: 34151693
[No Abstract] [Full Text] [Related]
19. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
20. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
